Company overview
TQ Therapeutics develops innovative technologies for cell and gene therapy manufacturing, including the EXiVO extracorporeal approach for ultra-fast, automated processing of autologous T cells using mRNA-LNP. Their platform enables bedside delivery of personalized therapies in under five hours by integrating blood collection, cell isolation, genetic modification, and reinfusion. They license proprietary affinity-based cell selection technology to partners like Fresenius Kabi for scalable T-cell isolation from whole blood.
Tq Therapeutics is listed in the NovaPharmaNews Supplier Hub as a CDMO & Manufacturing partner serving United States & Americas. Core focus areas include tq therapeutics, cell therapy platform, exivo technology, t-cell isolation, gene therapy manufacturing, car-t bedside.
Industry categories: CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://tqtherapeutics.com
- Categories
- CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- tq therapeutics, cell therapy platform, exivo technology, t-cell isolation, gene therapy manufacturing, car-t bedside
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What is TQ Therapeutics' core technology for cell therapy?
- TQ Therapeutics' EXiVO platform uses extracorporeal in-vivo gene therapy, enabling automated, bedside processing of T cells from whole blood with transient mRNA-LNP modification in under five hours.
- What partnerships does TQ Therapeutics have for manufacturing?
- Fresenius Kabi has an exclusive license to TQ's affinity- and column-based T-cell isolation technology, integrating it into the Cue Cell Processing System for scalable cell therapy production.
- What therapeutic applications does TQ Therapeutics target?
- The company focuses on autologous mRNA-T-cell therapies for various indications, aiming to deliver personalized immunotherapies like CAR-T directly at the bedside.
Related editorial coverage
- ASGCT 2026: Gene Therapy Manufacturing Innovations Emerge
- ASGCT 2026: Gene Therapy Manufacturing Advances to Watch
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
Explore lab tools and QA/QC resources for R&D teams.
